Peter Wipf, PhD

Distinguished University Professor, University of Pittsburgh

Peter Wipf, PhD

Office: 758 CHVRN
Phone: 412-624-8606

Department of Chemistry


Univ. of Zürich, Dipl. Chem. 1984
Univ. of Zürich, PhD 1987
Univ. of Virginia, Postdoc 1990

I have the specific training, expertise, and proven track record in medicinal chemistry, structure-based drug design, and complex natural and unnatural product synthesis to design, synthesize and evaluate small molecule therapeutics. I have led an independent research group since 1990, and published >500 peer-reviewed papers and patents. My group has pursued medicinal chemistry projects since 1995, and one of our compounds, PX-866, moved on to several Phase II clinical trials for the treatment of cancer. Since 2002, I am the Director of the Center for Chemical Methodologies and Library Development (UPCMLD), and the co-leader of the University of Pittsburgh Chemical Diversity Center (UPCDC), a Participant in NCI’s Chemical Biology Consortium. Since 2012, I am also a co-leader of the Cancer Therapeutics Program at the University of Pittsburgh Cancer Institute. I was one of two founding members of the University of Pittsburgh Drug Discovery Institute (UP-DDI) in 2004. This track record, as well as my results from other ongoing and past programs, clearly demonstrate my commitment to interdisciplinary biomedical research, as well as my ability to interact with a diverse set of colleagues in biology, chemistry, pharmacology, and medicine. We remain committed to the search for innovative cures harnessing the power of small molecules. In summary, I have a demonstrated record of developing and deploying the tools of synthetic and medicinal chemistry to investigate important hypotheses in the biological and health-related sciences.

  1. Optimization of pyrazole-containing 1,2,4-triazolo-[3,4-b]thiadiazines, a new class of STAT3 pathway inhibitors. LaPorte MG, Wang Z, Colombo R, Garzan A, Peshkov VA, Liang M, Johnston PA, Schurdak ME, Sen M, Camarco DP, Hua Y, Pollock NI, Lazo JS, Grandis JR, Wipf P, Huryn DM. Bioorganic & medicinal chemistry letters. 2016; 26(15):3581-5. NIHMSID: NIHMS801142 PubMed [journal] PMID: 27381083 PMCID: PMC4964800
  2. Total synthesis, biosynthesis and biological profiles of clavine alkaloids. McCabe SR, Wipf P. Organic & biomolecular chemistry. 2016; 14(25):5894-913. NIHMSID: NIHMS790180 PubMed [journal] PMID: 27215547 PMCID: PMC4917493
  3. Photooxygenation of an amino-thienopyridone yields a more potent PTP4A3 inhibitor. Salamoun JM, McQueeney KE, Patil K, Geib SJ, Sharlow ER, Lazo JS, Wipf P. Organic & biomolecular chemistry. 2016; 14(27):6398-402. NIHMSID: NIHMS795051 PubMed [journal] PMID: 27291491 PMCID: PMC4935606
  4. Synthesis and Evaluation of Potent KCNQ2/3-Specific Channel Activators. Kumar M, Reed N, Liu R, Aizenman E, Wipf P, Tzounopoulos T. Molecular pharmacology. 2016; 89(6):667-77. PubMed [journal] PMID: 27005699
  5. Mitochondrial targeting of XJB-5-131 attenuates or improves pathophysiology in HdhQ150 animals with well-developed disease phenotypes. Polyzos A, Holt A, Brown C, Cosme C, Wipf P, Gomez-Marin A, Castro MR, Ayala-Peña S, McMurray CT. Human molecular genetics. 2016; 25(9):1792-802. PubMed [journal] PMID: 26908614